Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions

Strategic alliance to expand Boston Scientific portfolio of remote monitoring solutions

Aug 03, 2015, 16:30 ET from Boston Scientific Corporation

MARLBOROUGH, Mass., Aug. 3, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related diagnostic and monitoring offerings.

Through this alliance, Boston Scientific will expand its commercial presence into the $1 billion cardiac diagnostics and monitoring market by gaining access to a wireless monitoring portfolio linked to an integrated remote monitoring platform.  This relationship with Preventice Solutions reinforces Boston Scientific's commitment to demonstrating the benefits of remote monitoring for a broad range of patients.

Preventice Solutions, a privately held company, is a leading developer of mobile health solutions and services and offers a full portfolio of wearable cardiac monitors, including Holter monitors, cardiac event monitors and mobile cardiac telemetry. These technologies are complemented by monitoring services including data transmission, surveillance, reporting, interpretation and integration into a healthcare provider's workflow.

"As our healthcare environment continues to evolve, healthcare practitioners, administrators and payors are looking for solutions that identify relevant clinical insights from large volumes of patient data and integrate those insights to improve clinical decision-making," said Joe Fitzgerald, executive vice president and president, Rhythm Management, Boston Scientific. "This collaboration with Preventice Solutions, which has an infrastructure optimized to monitor hundreds of thousands of patients each year, is a critical step in our effort to improve patient outcomes and reduce healthcare costs."

Cardiac monitoring is a critical component required for the diagnosis of many arrhythmias that require clinical intervention. Preventice Solutions' portfolio includes the PatientCare Platform and the BodyGuardian® family of products.

About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and the strategic alliance with Preventice Solutions. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS Media: Trish Backes Boston Scientific Corporation 651-582-5887 (office) Trish.Backes@bsci.com

Investors: Susie Lisa, CFA Boston Scientific Corporation (508) 683-5565 (office) investor_relations@bsci.com

SOURCE Boston Scientific Corporation



RELATED LINKS

http://www.bostonscientific.com